Mesoblast asks for trading halt as PDUFA date slides by. What's up?
Everything was all lined up for Mesoblast’s Wednesday PDUFA date regarding its acute graft-versus-host disease candidate remestemcel-L, or Ryoncil. But with no word in any direction on any FDA actions, the biotech is preparing its stock for the delayed ruling.
Mesoblast $MESO has asked the Australian stock exchange to place its shares in a trading halt until the company can make an announcement about the Ryoncil review. That announcement will likely come on Monday at the latest, the company said in a release.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,400+ biopharma pros reading Endpoints daily — and it's free.